4.8 Article

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

期刊

ONCOGENE
卷 27, 期 58, 页码 7274-7284

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2008.333

关键词

polycomb group protein; histone; EZH2; E-cadherin; epigenetics

资金

  1. National Institutes of Health [R01 CA97063, U01 CA111275, P50 CA69568]
  2. Department of Defense [PC040517, PC051081, PC060266, R01CA107469]

向作者/读者索取更多资源

Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据